Krsnaa Diagnostics
779.10
-35.70(-4.38%)
Market Cap₹2,643.10 Cr
PE Ratio31.52
Company Performance:
1D-4.38%
1M-8.28%
6M-2.72%
1Y-5.80%
5Y-21.06%
View Company Insightsright
More news about Krsnaa Diagnostics
05Aug 25
Krsnaa Diagnostics Secures Contract for Free Diagnostic Services in Rajasthan
Krsnaa Diagnostics and Telecommunications Consultants India Ltd. (TCIL) have signed an agreement with the National Health Mission, Rajasthan to provide laboratory services under the Free Diagnostics Initiative. The contract involves implementing a HUB and SPOKE Model for laboratory services across Rajasthan, aiming to enhance accessibility to diagnostic services, especially in remote areas. The exact contract size is undisclosed due to the project's novel nature. This agreement represents a significant opportunity for Krsnaa Diagnostics to expand its presence in Rajasthan's public health sector.
07Jul 25
Krsnaa Diagnostics Secures License to Provide Free Lab Services in Rajasthan
Krsnaa Diagnostics has been awarded a new license by the Rajasthan government to provide free laboratory services across the state. This development follows a recent court ruling and aligns with the company's mission to improve healthcare accessibility. The license allows Krsnaa Diagnostics to operate and offer a range of diagnostic services at no cost to patients throughout Rajasthan, potentially benefiting residents who previously faced financial barriers to essential tests. This strategic expansion strengthens Krsnaa's position in the public health sector and demonstrates its commitment to partnering with state authorities.
12May 25
Krsnaa Diagnostics Reports Strong Q4 Results with Improved EBITDA, Net Profit, and Recommends Dividend
Krsnaa Diagnostics announced robust Q4 financial results, with revenue increasing 12% year-over-year to 1.86 billion rupees. EBITDA grew 21.3% to 530 million rupees, with an improved margin of 28.48%. Net profit rose 10.7% to 207 million rupees. The company's annual revenue increased by 25.65% to 636.40 crore rupees. A dividend of 2.75 rupees per share has been recommended.
Krsnaa Diagnostics
779.10
-35.70
(-4.38%)
1 Year Returns:-5.80%
Industry Peers
Dr. Lal Path Labs
3,108.10
(-1.54%)
Metropolis Healthcare
1,938.20
(-0.61%)
Thyrocare Technologies
1,243.90
(-2.49%)
Krsnaa Diagnostics
779.10
(-4.38%)
Suraksha Diagnostic
300.55
(+0.13%)
3B BlackBio DX
1,378.00
(+0.52%)
Sastasundar Ventures
305.30
(-1.52%)
Choksi Laboratories
163.30
(-3.32%)